John Cavan - Hepion Pharmaceuticals Chief Officer
| HEPA Stock | USD 0.67 0.03 4.69% |
Executive
Mr. John T. Cavan is Chief Financial Officer of the company. From January 2016 to April 2016, Mr. Cavan served in the capacity of Interim CFO. Prior to joining ContraVir, Mr. Cavan was a consultant with The Pine Hill Group from February 2012 to March 2016 where he was instrumental in completing multiple strategic and financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, from June 2006 until February 2012, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. and as Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. where he was instrumental in the companys initial public offering, through which Aegerion achieved a 2 billion market capitalization. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products and Nestl U.S.A since 2016.
| Age | 66 |
| Tenure | 8 years |
| Address | 399 Thornall Street, Edison, NJ, United States, 08837 |
| Phone | 732 902 4000 |
| Web | https://hepionpharma.com |
John Cavan Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Cavan against Hepion Pharmaceuticals stock is an integral part of due diligence when investing in Hepion Pharmaceuticals. John Cavan insider activity provides valuable insight into whether Hepion Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Hepion Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hepion Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Cavan over three months ago Acquisition by John Cavan of 101221 shares of Hepion Pharmaceuticals subject to Rule 16b-3 |
Hepion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.9282) % which means that it has lost $0.9282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8952) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -2.84. The current year's Return On Capital Employed is expected to grow to -3.59. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 24 M, whereas Non Currrent Assets Other are forecasted to decline to about 228.6 K.Similar Executives
| Found 14 records | EXECUTIVE Age | ||
| Kimberly Davis | Zura Bio Limited | 56 | |
| Candice Masse | Elevation Oncology | N/A | |
| Verender Badial | Zura Bio Limited | 52 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Esq CPA | Ocean Biomedical | 59 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Kevin CPA | Enveric Biosciences | 60 | |
| MD MBA | Ocean Biomedical | 59 | |
| Robert Yang | Elevation Oncology | N/A | |
| Biren Shah | Elevation Oncology | N/A | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| David Brady | Zura Bio Limited | N/A | |
Management Performance
| Return On Equity | -1.9 | ||||
| Return On Asset | -0.93 |
Hepion Pharmaceuticals Leadership Team
Elected by the shareholders, the Hepion Pharmaceuticals' board of directors comprises two types of representatives: Hepion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hepion. The board's role is to monitor Hepion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hepion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hepion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc BSc, CEO Pres | ||
| Patrick Mayo, Senior Pharmacology | ||
| John Cavan, Chief Officer | ||
| Sharen Pyatetskaya, Director Relations | ||
| Todd MD, Chief Officer | ||
| Daniel Trepanier, Senior Development | ||
| Daren Ure, Chief Officer | ||
| MD FACP, Scientific Director | ||
| John SullivanBolyai, Chief Medical Officer | ||
| Launa Aspeslet, Chief Officer | ||
| Stephen MD, Member Director | ||
| John CPA, Executive Chairman |
Hepion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hepion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.9 | ||||
| Return On Asset | -0.93 | ||||
| Current Valuation | 7.07 M | ||||
| Shares Outstanding | 6.96 M | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 7.85 % | ||||
| Number Of Shares Shorted | 64.34 K | ||||
| Price To Earning | (3.01) X | ||||
| Price To Book | 2.11 X | ||||
| EBITDA | (49.26 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.40) | Return On Assets (0.93) | Return On Equity (1.90) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.